About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
NKTR - Nektar Therapeutics| Previous Close | $18.81 | Open | $18.76 |
| Volume | 46.9K | Market Cap | 3.464B |
| Yield | Last Dividend |
| Leerink Partners Stick to Their Hold Rat... | 04/06/21 |
| Leerink Partners Stick to Their Hold Rating for Nektar Therapeutics | |
| Nektar Therapeutics (NASDAQ:NKTR) Announ... | 02/28/21 |
| Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter... | |
| Nektar Posts Better-Than-Feared Quarterl... | 02/26/21 |
| Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts??? expectations for revenues. Shares of the biophar... | |
| Nektar Therapeutics Will stock surge bef... | 02/24/21 |
| Nektar Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| The Daily Biotech Pulse: Lily-Rigel Lice... | 02/18/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Adv... | |
| Mizuho Securities Stick to Their Buy Rat... | 02/18/21 |
| Mizuho Securities Stick to Their Buy Rating for Nektar Therapeutics | |
| Nektar Announces Agreement for Phase 2/3... | 02/17/21 |
| SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboratio... | |
| Nektar Announces Collaboration with SFJ ... | 02/17/21 |
| SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development... | |
| Nektar Therapeutics (NASDAQ:NKTR) CEO Se... | 02/07/21 |
| Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 150,000 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 3rd. Th... | |
| Gil M. Labrucherie Sells 50,000 Shares o... | 02/04/21 |
| Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 50,000 shares of the firm???s stock in a transaction that occurred on Tuesday, February ... | |
| Insider Selling: Nektar Therapeutics (NA... | 02/01/21 |
| Nektar Therapeutics (NASDAQ:NKTR) CAO Jillian B. Thomsen sold 75,000 shares of the company???s stock in a transaction that occurred on Thursday, Janua... | |
| Insider Selling: Nektar Therapeutics (NA... | 12/18/20 |
| Nektar Therapeutics (NASDAQ:NKTR) Director Curet Myriam sold 1,560 shares of Nektar Therapeutics stock in a transaction on Tuesday, December 15th. The... | |
| The Week Ahead In Biotech: Supernus, San... | 11/08/20 |
| Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of gua... | |
| Nektar Therapeutics EPS beats by $0.16, ... | 11/05/20 |
| Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16. Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the rec... | |
| Growing M&A momentum drives gains in Rhe... | 10/12/20 |
| Growing M&A momentum drives gains in Rhenman???s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activi... | |
| This Is What Hedge Funds Bought And Sold... | 08/16/20 |
| This Is What Hedge Funds Bought And Sold In The Second Quarter Tyler Durden Sun, 08/16/2020 - 13:00 In addition to the widely publicized changes in Be... | |
| Why Is Nektar (NKTR) Up 12% Since Last E... | 06/06/20 |
| Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Nektar Therapeutics (NKTR) Q1 2020 Earni... | 05/08/20 |
| NKTR earnings call for the period ending March 31, 2020. | |
| Cerus Corporation Announces Strategic Or... | 03/02/20 |
| Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promo... | |
| Analysts Estimate Nektar Therapeutics (N... | 02/20/20 |
| Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with th... | |
| Nektar Therapeutics (NKTR) Stock Sinks A... | 02/06/20 |
| Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day. | |
| Nektar Therapeutics Pullback May Be Shor... | 01/23/20 |
| Nektar has struggled to gain momentum since its early August sell-off | |
| Why This Opioid Painkiller Is Killing Ne... | 01/15/20 |
| No summary available. | |
| Nektar Slumps As FDA Panel Gives Thumbs ... | 01/15/20 |
| Shares of midcap biopharma Nektar Therapeutics (NASDAQ: NKTR ) are retreating sharply following a negative verdict handed down by FDA staffers for its... | |
| Nektar stock drops more than 10% as FDA ... | 01/14/20 |
| Nektar Therapeutics [sL nktr] shares fell in the extended session Tuesday following a report that a Food and Drug Administration advisory panel voted ... | |
| Stocks making the biggest moves after th... | 01/14/20 |
| Check out the companies making headlines after the bell. | |
| NIO : Thinking about buying stock in Bil... | 01/13/20 |
| NEW YORK, Jan. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BILI, MSFT, NIO, NKTR, and NVDA. To see how InvestorsO... | |
| The Week Ahead In Biotech: JPMorgan Heal... | 01/12/20 |
| Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech ... | |
| Shareholder Alert: Robbins LLP Reminds I... | 01/10/20 |
| SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $NKTR #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that purchasers of Nektar... | |
| Nektar Therapeutics Options Pop as Stock... | 01/10/20 |
| Nektar and Bristol-Myers Squibb will expand an ongoing late-stage collaborative trial | |
| Buy rating | 04/06/21 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $20.00 to $21.00 | |
| Hold rating | 02/22/21 |
| Benchmark downgrades from Buy to Hold rating and announces Price Target of $26.00 | |
| Date | 2021-02-25 (AMC) | Est. (EPS/Rev.) | ($0.68)/ 30.01M |
| Actual (EPS/Rev.) | $-0.65/ $23.46 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Silent swinger | hasmat | 43.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
